Navigation Links
ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds,for Solid Tumors Are to be Reported at ASCO

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 24, 2007 - ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics using its Tumor-Activated Prodrug (TAP) technology, today announced that clinical findings for three different TAP compounds for the treatment of solid tumors are to be reported at the 43rd American Society of Clinical Oncology (ASCO) Annual Meeting to take place June 1-5, 2007 in Chicago, IL.

Trastuzumab-DM1 (abstract #1042)

"A phase I study of trastuzumab-MCC-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (BC)."

-- Saturday, June 2, 2:00-6:00 pm: Breast Cancer - Metastatic General Poster Session (poster #G4).

-- Trastuzumab-DM1 is in development by Genentech.

HuC242-DM4 (abstract #3062)

"A phase I study of a CanAg-targeted immunoconjugate, huC242-DM4, in patients with Can Ag-expressing solid tumors."

-- Sunday, June 3, 8:00 am-12:00 noon: Developmental Therapeutics: Immunotherapy General Poster Session (poster #F14).

-- HuC242-DM4 is wholly owned by ImmunoGen.

HuN901-DM1 (abstract #18084)

"Phase II trial of huN901-DM1 in patients with relapsed small cell lung cancer (SCLC) and CD56-positive small cell carcinoma."

-- To be published as abstract in the Journal of Clinical Oncology.

-- HuN901-DM1 is wholly owned by ImmunoGen.

About ImmunoGen's TAP Technology

ImmunoGen created its TAP technology to enhance the anticancer activity of tumor-targeting antibodies while maintaining a favorable tolerability profile. The Company attaches to an antibody one of ImmunoGen's proprietary cell-killing agents. The antibody serves to deliver the agent specifically to cancer cells and the agent serves to kill the cancer cells. The agent is attached using one of the Company's "linkers." ImmunoGen has developed alte
'"/>




Page: 1 2 3

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:7/28/2014)... , July 28, 2014  Air Products (NYSE: ... of medical oxygen is vital to any healthcare facility. ... that not only improve the efficiency of its oxygen ... will highlight these systems—including systems for emergency oxygen ... loss—from August 4-5 at the 51 st ...
(Date:7/28/2014)... 28, 2014 Research and Markets  has announced ... 2014-2018" report to their offering. ... that leads to inflammation and pain in the human body,s ... addition, it causes inflammation of the tissues that surround the ... symptoms of RA begin slowly, usually just mild pain around ...
(Date:7/28/2014)... , July 28, 2014  TNI BioTech, Inc. ... company focused on the development, marketing and distribution ... filed definitive proxy materials with the Securities and ... Meeting of Shareholders to be held on Thursday, ... Time. The record date for determining those shareholders ...
Breaking Medicine Technology:Air Products Highlights Its Medical Oxygen Supply Systems for Emergency Oxygen Supply and Reduced Oxygen Loss at ASHE 2Air Products Highlights Its Medical Oxygen Supply Systems for Emergency Oxygen Supply and Reduced Oxygen Loss at ASHE 3Global Rheumatoid Arthritis Drugs Market 2014-2018 2TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 2TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 3
... The U.S. Food and Drug Administration today announced that monthly ... Letairis tablets (ambrisentan), used to treat high blood pressure in ... hypertension, or PAH). (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... the FDA said that the drug poses only a low ...
... 4, 2011 Sigma-Aldrich Corporation (Nasdaq: SIAL ) ... 31st Annual Cowen and Company Healthcare Conference ... Place, Boston, MA, presenting at 10:15 AM (EST). Barclays ... the Loews Miami Hotel, Miami, FL, presenting at 10:15 AM ...
Cached Medicine Technology:FDA Modifies Boxed Warning For Pulmonary Arterial Hypertension Drug Letairis 2FDA Modifies Boxed Warning For Pulmonary Arterial Hypertension Drug Letairis 3
(Date:7/28/2014)... 29, 2014 The “Tissue ... Hybridization, Digital pathology & Workflow, Special Staining), ... Cancer, Non Small Cell Lung Cancer and ... Pharmaceutical companies, Research Laboratories, Contract Research Organizations ... Europe, BRIC, Japan & RoW) - Trends ...
(Date:7/28/2014)... Ariz (PRWEB) July 28, 2014 ... on a new camp property in Cornville, AZ. ... seriously ill children with the opportunity to attend ... campers and families. The organization offers a variety ... 6-15 with chronic and life threatening illnesses including: ...
(Date:7/28/2014)... 28, 2014 An estimated 68,000 women ... metastatic breast and prostate cancers – an aggressive form ... spread to other parts of the body, such as ... Drexel University College of Medicine have developed ... inhibits metastatic progression by blocking tumor cells from “re-seeding.” ...
(Date:7/28/2014)... a surgical procedure to treat severe chronic migraine headaches ... of the time in patients treated at Massachusetts General ... Plastic and Reconstructive Surgery report that more than half ... all of whom had headaches associated with compression of ... later. The team,s paper has received advance online ...
(Date:7/28/2014)... Glutamine is the most abundant single amino ... conditionally essential during times when the body undergoes large ... Immune System Support. , Having a heavy work out ... with additional glutamine may be advantageous. Glutamine supplementation may ... digestion and immune system function. Stress on the body ...
Breaking Medicine News(10 mins):Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 2Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 3Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 4Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 5Health News:Camp Soaring Eagle Announces New Camp Site 2Health News:Camp Soaring Eagle Announces New Camp Site 3Health News:Drexel Scientists Develop Compound to Stop Spread of Metastatic Cancer Cells 2Health News:Drexel Scientists Develop Compound to Stop Spread of Metastatic Cancer Cells 3Health News:Non-endoscopic migraine surgery provides significant symptom relief 2Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 2Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 3
... the blood is not associated with a reduced risk ... online May 27 in the Journal of the ... high doses of vitamin D may reduce the risk ... the relationship have reported inconsistent results. , In a ...
... finds evidence of slight link between higher concentrations, aggressive ... Men with a high blood concentration of vitamin D ... Cancer Institute researchers report. , Previous laboratory studies had ... prostate cancer risk, but epidemiological studies of that association ...
... Researchers have uncovered a completely unexpected way that the brain ... protective protein to nearby neurons. , Astrocytes are a type ... one of their roles is to chew up damaged nerves ... damaged area. , Roger Chung and colleagues have now ...
... higher in low-expenditure areas than in high-expenditure ones, study ... levels of spending on medical care don,t improve patients, ... who conducted a survey of Medicare beneficiaries. , Per ... United States and differences in health don,t account for ...
... review suggests they may help cancer cells resist chemo, ... new review of existing research suggests that cancer patients ... of antioxidants. , Although multivitamins may be all right ... or E supplements can spell trouble, said review author ...
... Environmentally friendly is not a phrase normally used to ... discovery at Tel Aviv University, the chemical industry is ... Arkadi Vigalok from the School of Chemistry at Tel ... to make certain steps of a complicated chain of ...
Cached Medicine News:Health News:No association found between vitamin D concentration in blood and risk of prostate cancer 2Health News:Vitamin D Status Not Associated With Lower Prostate Risk 2Health News:Spending Doesn't Improve Patients' Perception of Care 2Health News:Cancer Patients Should Steer Clear of Antioxidants 2Health News:Cancer Patients Should Steer Clear of Antioxidants 3Health News:1 small step for a lab science, 1 green leap for mankind 2
... to use: when presented in convenient, ... easy to pick up directly from ... the 96 tips are loaded without ... with a security sticker. Fully autoclavable, ...
This pipette tip facilitates the loading of samples onto polyacrylamide gels for DNA sequencing. The Geloader Tip has a 15 mm capillary with a defined diameter of less than 0.3 mm. The flexibility of...
1200 L, Racked, 96 tips/rack, 10 racks/box Recommended for 1200 L SofTouch electronic pipettes....
Designed to fit the Brinkmann Tranferpette and Treff Multi-Channel 300 L Pipettors, this tip provides extra space for repeat pipetting....
Medicine Products: